Association between gene mutation and rare heart disease found
A strong association between a genetic mutation and a rare kind of heart muscle disease has been discovered by researchers at the University of Colorado Anschutz Medical Campus.
The finding could improve understanding of the disease and lead to new treatments.
"There are many kinds of cardiomyopathies that can lead to heart failure so this is a serious problem," said Teisha J. Rowland, PhD, a post-doctoral fellow in the lab of Luisa Mestroni, MD, and Matthew R. G. Taylor, MD, PhD, at the University of Colorado School of Medicine and first author of the study.
The Mestroni and Taylor lab sequenced nearly 5,000 genes in 335 patients with a family history of heart muscle disease, looking for mutations that could cause a variety of cardiomyopathies.
"Many kinds of heart disease are caused by genetics. When that happens, the disease is often more severe and happens at an earlier age," said Rowland, who studies genetics and cardiology. "So we look at the DNA in entire families to see what sort of genetic variants those with the illness have in common."
They found that several people with left ventricular noncompaction (LVNC) had a mutation in a gene called Obscurin. Obscurin is part of the sarcomere, the basic unit of striated muscles that pull and glide past each other when muscles contract. That includes the heart muscle. If there is a mutation in Obscurin that process may not function properly.
"We found a strong association between this gene, which has not been studied much, and this rare form of genetic heart disease," Rowland said. "Left ventricular noncompaction is thought to happen during early human development. It would be interesting to see if mutated Obscurin affects heart formation during development."
Rowland said the findings point to areas warranting further attention.
"We expect this will ultimately improve our understanding of the disease," she said.
Original publication
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Breakthrough for an Alternative to Crude Oil & Palm Oil - OLIPI Receives €1.8 Million Seed Funding for Further Development of CO2-Neutral Climate Oil
Max-Planck-Institut für Biologie des Alterns - Köln, Germany

Scientists produce clearest-ever images of enzyme that plays key roles in aging, cancer

Growth capital for innovative bio-based ingredients - NBank Capital acquires a stake in Lignopure GmbH

Innovative Blood Test Based on Infrared Light - Monitoring health and detect disorders at an early stage

PreComb Therapeutics secures CHF 2.2 Mio seed financing - Biotech startup to advance personalized medicine for cancer patients
Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
